Is Tremelimumab approved by the FDA?

Tremelimumab (brand name: Imjudo) is indeed FDA-approved. It is a monoclonal antibody that belongs to the class of drugs known as anti-CTLA-4 monoclonal antibodies. This medication is used in adults for the treatment of specific types of liver and lung cancers, particularly when the cancer has spread to other parts of the body (metastatic) or cannot be removed by surgery. Tremelimumab was approved by the FDA on October 21, 2022.

What is Tremelimumab? 

Tremelimumab works by targeting CTLA-4, a protein that normally helps keep the immune system in check. By inhibiting CTLA-4, tremelimumab enhances the immune system's ability to attack and destroy cancer cells. This mechanism can also cause the immune system to attack healthy tissues and organs, leading to potential side effects.

Dosage and Administration: 

Tremelimumab is administered as an intravenous solution with a concentration of 20 mg/mL. The specific dosage and treatment schedule are determined by the healthcare provider based on the patient's weight and overall health status. The medication is given through an injection into a vein, and patients are closely monitored for any immediate side effects during and after the administration.

Side Effects: 

Tremelimumab can cause a range of side effects, some of which may be severe or life-threatening. Common side effects include:

• Abnormal blood tests
• Nausea, diarrhea
• Feeling weak or tired
• Muscle, bone, or joint pain
• Stomach pain, loss of appetite
• Itching, rash

Serious Side Effects: 

Patients should seek immediate medical attention if they experience:

• Signs of an allergic reaction (hives, difficulty breathing, swelling in the face or throat)
• Severe skin reactions (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling)
• Symptoms affecting multiple parts of the body (skin rash, fever, swollen glands, muscle aches, severe weakness, unusual bruising, yellowing of the skin or eyes)
• Signs of organ inflammation or damage (lungs, liver, pancreas, kidneys, intestines, thyroid, adrenal glands)

Warnings: 

Tremelimumab can cause the immune system to attack healthy organs and tissues, potentially leading to serious or life-threatening side effects. Patients should inform their doctor if they have a history of autoimmune disorders or nerve-muscle disorders.

Before Taking Tremelimumab: 

Patients should discuss their medical history with their doctor, especially if they have:

• Autoimmune disorders (e.g., Crohn's disease, ulcerative colitis, lupus)
• Nerve-muscle disorders (e.g., myasthenia gravis, Guillain-Barré syndrome)

Women should use effective birth control while receiving tremelimumab and for at least 3 months after the last dose, as the medication can harm an unborn baby. Breastfeeding is not recommended during treatment and for at least 3 months after the last dose.

Monitoring and Follow-Up: 

Regular medical tests are necessary to monitor the patient's response to treatment and detect any potential side effects. Treatment schedules and dosages may be adjusted based on the test results and the patient's condition.

Conclusion: 

Tremelimumab (Imjudo) is an FDA-approved treatment for certain types of liver and lung cancers. Approved on October 21, 2022, it offers a targeted approach to enhancing the immune system's ability to fight cancer. Patients undergoing treatment with tremelimumab should be closely monitored for side effects and maintain open communication with their healthcare provider to manage any adverse reactions effectively.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!